Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 81

Sort by

Sort Order Select

Journal Articles

Fixed-duration subcutaneous (SC) mosunetuzumab, with maintenance therapy, in patients (pts) with previously untreated high-tumor burden follicular lymphoma (HTB FL): Longer follow-up and exploratory circulating tumor (ct)DNA analysis of the Phase II MorningSun study

John M. Burke, Jeff Sharman, Bertrand Anz, Richard Zuniga, Aung Tun, David Wright, Prachi Jani, Juliana Biondo, Mei Wu, Yong Mun, Vivek S. Chopra, Rona Farighi, Jose Villasboas Bisneto, Elizabeth Budde, Ian Flinn

Blood (2025) 146 (Supplement 1): 228.

https://doi.org/10.1182/blood-2025-228

Published: 2025

Journal Articles

A Phase 1 study evaluating NT-I7 (efineptakin alfa), a long-acting human IL-7, post-tisagenlecleucel (tisa-cel), post-axicabtagene ciloleucel (axi-cel), or post-lisocabtagene maraleucel (liso-cel) in Relapsed/Refractory large B-cell lymphoma

Zachary Crees, Armin Ghobadi, Elizabeth Budde, Ahmed Galal, Chenyu Lin, Donghoon Choi, Sun-Kyoung Im, Hye Jeong, Alex Oh, Michael Rettig, John DiPersio

Blood (2025) 146 (Supplement 1): 926.

https://doi.org/10.1182/blood-2025-926

Published: 2025

Journal Articles

Fixed-duration subcutaneous mosunetuzumab continues to demonstrate high rates of durable responses in patients with relapsed/refractory follicular lymphoma after ≥2 prior therapies: 3-year follow-up from a pivotal Phase II study

Blood (2025) 146 (Supplement 1): 5353.

https://doi.org/10.1182/blood-2025-5353

Published: 2025

Journal Articles

Fixed treatment duration mosunetuzumab continues to demonstrate clinically meaningful outcomes in patients with relapsed/refractory (R/R) follicular lymphoma (FL) after ≥2 prior therapies: 5-year follow-up of a pivotal Phase II study

Blood (2025) 146 (Supplement 1): 5352.

https://doi.org/10.1182/blood-2025-5352

Published: 2025

Journal Articles

Interim analysis of the phase II study of glofitamab, lenaliomide and venetoclax (GLOVe) in untreated patients w/ high-risk mantle cell lymphoma. response and safety outcomes after the completion of stage 1 of 2 enrollment.

Tycel Phillips, Lu Chen, Tiffanie Barnhizer, Alex Herrera, Geoffrey Shouse, Daniel Ermann, Reem Karmali, Adam Kittai, Manali Kamdar, Diane Smith, James Godfrey, Brian Sworder, Swetha Thiruvengadam, John Baird, Avyakta Kallam, Elizabeth Budde, Alexey Danilov

Blood (2025) 146 (Supplement 1): 883.

https://doi.org/10.1182/blood-2025-883

Published: 2025

Journal Articles

Improvements in health-related quality of life (HRQoL) in the SUNMO study: Subcutaneous (SC) mosunetuzumab plus polatuzumab vedotin (Mosun-Pola) vs rituximab, gemcitabine and oxaliplatin (R-GemOx) in patients with relapsed/refractory (R/R) large B-cell lymphoma (LBCL) after at least one prior therapy

Elizabeth Budde, Jason Westin, Huilai Zhang, Dai Maruyama, Eduardo M. Rego, Huangming Hong, Hideki Goto, Mark Fesler, Boone Goodgame, Zhiming Li, Adam Olszewski, Joan Ashby, Shen Yin, Wahib S. Ead, Martin Janousek, Song Pham, Connie L. Batlevi, Michael C. Wei, Won-Seog Kim

Blood (2025) 146 (Supplement 1): 5509.

https://doi.org/10.1182/blood-2025-5509

Published: 2025

Journal Articles

Trial-in-progress: A phase 2 randomized trial of remodeling intestinal microbiota using fecal microbiome transplant (FMT) among recipients of chimeric antigen receptor T cells (CAR T)

Karamjeet Sandhu, Xinran Qi, Sally Mokhtari, Xin-Zi Emily Tang, John Baird, Alexander Khoruts, Elizabeth Budde, Robert Jenq

Blood (2025) 146 (Supplement 1): 5507.

https://doi.org/10.1182/blood-2025-5507

Published: 2025

Journal Articles

Long-term follow-up with sustained progression-free survival (PFS) benefit after subcutaneous (SC) mosunetuzumab in combination with polatuzumab vedotin compared with rituximab plus polatuzumab vedotin in patients with relapsed or refractory (R/R) B-cell non-Hodgkin lymphoma

Nilanjan Ghosh, Julio Chavez, Mariana Bastos-Oreiro, Catherine Diefenbach, Izidore S. Lossos, Nirav Shah, Sarit Assouline, Adam Olszewski, Seema Naik, Song Pham, Michael C. Wei, Connie L. Batlevi, Iris To, Wahib S. Ead, Sneha Makadia, Elicia Peneul, Elizabeth Budde

Blood (2025) 146 (Supplement 1): 1020.

https://doi.org/10.1182/blood-2025-1020

Published: 2025

Journal Articles

High efficacy of blinatumomab combined with pembrolizumab in patients with relapsed/refractory (r/r) B cell acute lymphoblastic leukemia (B-ALL): primary analysis of a Phase 1/2 study

Blood (2025) 146 (Supplement 1): 3352.

https://doi.org/10.1182/blood-2025-3352

Published: 2025

Journal Articles

Fixed-duration subcutaneous mosunetuzumab demonstrates sustained clinically meaningful outcomes in patients with previously untreated, low-tumor burden follicular lymphoma

Jose Villasboas Bisneto, John M. Burke, Aung Tun, Steve Liu, Jeff Sharman, Juliana Biondo, Prachi Jani, Mei Wu, Yong Mun, Vivek S. Chopra, Rona Farighi, Javier Munoz, Furhan Yunus, Ian Flinn, Elizabeth Budde

Blood (2025) 146 (Supplement 1): 1807.

https://doi.org/10.1182/blood-2025-1807

Published: 2025

Journal Articles

Promising response rates and manageable safety with mosunetuzumab plus lenalidomide (Mosun-Len) in patients with relapsed/refractory (R/R) follicular lymphoma (FL): US extension cohort from the Phase III CELESTIMO study

Blood (2025) 146 (Supplement 1): 1800.

https://doi.org/10.1182/blood-2025-1800

Published: 2025

Journal Articles

Fixed-duration intravenous mosunetuzumab plus polatuzumab vedotin combination therapy continues to demonstrate durable responses in patients with large B-cell lymphoma: 3-year follow-up from a Phase Ib/II study

Manali Kamdar, Julio Chavez, Adam Olszewski, Sarit Assouline, Izidore S. Lossos, Catherine Diefenbach, Dipenkumar Modi, Waleed Sabry, Seema Naik, Amitkumar Mehta, Sneha Makadia, Song Pham, Elicia Peneul, Hao Wu, Wahib S. Ead, Iris To, Dennis J. Houston, Connie Lee Batlevi, Elizabeth Budde

Blood (2025) 146 (Supplement 1): 3735.

https://doi.org/10.1182/blood-2025-3735

Published: 2025

Journal Articles

BAFFR-CAR T cells (PMB-CT01) show promising safety and anti-leukemia efficacy in relapsed/refractory B-cell ALL patients after CD19-targeted therapy failure, including CD19-negative disease

Ibrahim Aldoss, Xiuli Wang, Lu Chen, Joo Song, Karamjeet Sandhu, Alan Macias, Neguine Sanani, Baishakhi Barva, Min Guan, Ruby Espinosa, Sandrine Puverel, Qing Liu-Michael, Hazel (Ting-Ying) Cheng, Guido Marcucci, Elizabeth Budde, Larry Kwak, Stephen Forman

Blood (2025) 146 (Supplement 1): 813.

https://doi.org/10.1182/blood-2025-813

Published: 2025

Journal Articles

BAFFR-CAR T cells (PMB-CT01) demonstrate durable responses and manageable toxicities in relapsed/refractory B-cell lymphomas with prior CD19-directed therapy failure or CD19-negative disease

Elizabeth Budde, Marissa Del Real, John Baird, Lu Chen, Joo Song, Xiuli Wang, Swetha Thiruvengadam, Marie Hu, Alan Macias, Emanuela Marcucci, Soungchul Cha, Zhenyuan Dong, Teresa Kim, Baishakhi Barva, Sandrine Puverel, Qing Liu-Michael, Hazel (Ting-Ying) Cheng, Stephen Forman, Larry Kwak

Blood (2025) 146 (Supplement 1): 268.

https://doi.org/10.1182/blood-2025-268

Published: 2025

Journal Articles

Outcomes of CAR T-cell therapies after prior treatment with fixed-duration mosunetuzumab in patients with relapsed/refractory B-cell non-Hodgkin lymphoma

Adam Braun, Nancy Bartlett, Dai Chihara, Loretta Nastoupil, Mazyar Shadman, Dimitrios Tzachanis, Hunter Cochran, Jennifer Huang, Mei Wu, Michael C. Wei, Shen Yin, Jing Qi Hao, Qian Zhu, Yong Mun, Elizabeth Budde

Blood (2025) 146 (Supplement 1): 6261.

https://doi.org/10.1182/blood-2025-6261

Published: 2025

Journal Articles

CD19-CAR T cell therapy as a definitive consolidation in older adults with b-ALL in CR1 is safe and induces durable MRD- remission

Blood (2025) 146 (Supplement 1): 443.

https://doi.org/10.1182/blood-2025-443

Published: 2025

Journal Articles

High rates of financial toxicity and time toxicity in patients receiving chimeric antigen receptor therapy and bispecific antibodies for lymphoma and multiple myeloma: A prospective mixed methods study.

Blood (2025) 146 (Supplement 1): 6364.

https://doi.org/10.1182/blood-2025-6364

Published: 2025

Journal Articles

CAR T-cell therapy outcomes in adolescent and young adult patients with non-Hodgkin lymphoma

Lindsey Murphy, Molly Thornock, Xinyi Du, Alysia Bosworth, Lanie Lindenfeld, Matthew Mei, Leslie Popplewell, Nicole Karras, Anna Pawlowska, Alex Herrera, F. Wong, Stephen Forman, Elizabeth Budde, Saro Armenian

Blood (2025) 146 (Supplement 1): 1013.

https://doi.org/10.1182/blood-2025-1013

Published: 2025

Journal Articles

Subcutaneous Mosunetuzumab Leads to High Rates of Durable Responses, Low Rates of Cytokine Release Syndrome, and Non-Inferior Exposure Compared with Intravenous Administration in Patients with Relapsed/Refractory Follicular Lymphoma: Primary Analysis of a Pivotal Phase II

Blood (2024) 144 (Supplement 1): 1645.

https://doi.org/10.1182/blood-2024-194612

Published: 2024

Journal Articles

A Phase 2 Study of Loncastuximab Tesirine Plus Mosunetuzumab in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Blood (2024) 144 (Supplement 1): 1742.1.

https://doi.org/10.1182/blood-2024-198727

Published: 2024

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Fixed-duration subcutaneous (SC) mosunetuzumab, with maintenance therapy, in patients (pts) with previously untreated high-tumor burden follicular lymphoma (HTB FL): Longer follow-up and exploratory circulating tumor (ct)DNA analysis of the Phase II MorningSun study

A Phase 1 study evaluating NT-I7 (efineptakin alfa), a long-acting human IL-7, post-tisagenlecleucel (tisa-cel), post-axicabtagene ciloleucel (axi-cel), or post-lisocabtagene maraleucel (liso-cel) in Relapsed/Refractory large B-cell lymphoma

Fixed-duration subcutaneous mosunetuzumab continues to demonstrate high rates of durable responses in patients with relapsed/refractory follicular lymphoma after ≥2 prior therapies: 3-year follow-up from a pivotal Phase II study

Fixed treatment duration mosunetuzumab continues to demonstrate clinically meaningful outcomes in patients with relapsed/refractory (R/R) follicular lymphoma (FL) after ≥2 prior therapies: 5-year follow-up of a pivotal Phase II study

Interim analysis of the phase II study of glofitamab, lenaliomide and venetoclax (GLOVe) in untreated patients w/ high-risk mantle cell lymphoma. response and safety outcomes after the completion of stage 1 of 2 enrollment.

Trial-in-progress: A phase 2 randomized trial of remodeling intestinal microbiota using fecal microbiome transplant (FMT) among recipients of chimeric antigen receptor T cells (CAR T)

Long-term follow-up with sustained progression-free survival (PFS) benefit after subcutaneous (SC) mosunetuzumab in combination with polatuzumab vedotin compared with rituximab plus polatuzumab vedotin in patients with relapsed or refractory (R/R) B-cell non-Hodgkin lymphoma

High efficacy of blinatumomab combined with pembrolizumab in patients with relapsed/refractory (r/r) B cell acute lymphoblastic leukemia (B-ALL): primary analysis of a Phase 1/2 study

Fixed-duration subcutaneous mosunetuzumab demonstrates sustained clinically meaningful outcomes in patients with previously untreated, low-tumor burden follicular lymphoma

Promising response rates and manageable safety with mosunetuzumab plus lenalidomide (Mosun-Len) in patients with relapsed/refractory (R/R) follicular lymphoma (FL): US extension cohort from the Phase III CELESTIMO study

Fixed-duration intravenous mosunetuzumab plus polatuzumab vedotin combination therapy continues to demonstrate durable responses in patients with large B-cell lymphoma: 3-year follow-up from a Phase Ib/II study

BAFFR-CAR T cells (PMB-CT01) show promising safety and anti-leukemia efficacy in relapsed/refractory B-cell ALL patients after CD19-targeted therapy failure, including CD19-negative disease

BAFFR-CAR T cells (PMB-CT01) demonstrate durable responses and manageable toxicities in relapsed/refractory B-cell lymphomas with prior CD19-directed therapy failure or CD19-negative disease

Outcomes of CAR T-cell therapies after prior treatment with fixed-duration mosunetuzumab in patients with relapsed/refractory B-cell non-Hodgkin lymphoma

CD19-CAR T cell therapy as a definitive consolidation in older adults with b-ALL in CR1 is safe and induces durable MRD- remission

High rates of financial toxicity and time toxicity in patients receiving chimeric antigen receptor therapy and bispecific antibodies for lymphoma and multiple myeloma: A prospective mixed methods study.

CAR T-cell therapy outcomes in adolescent and young adult patients with non-Hodgkin lymphoma

Subcutaneous Mosunetuzumab Leads to High Rates of Durable Responses, Low Rates of Cytokine Release Syndrome, and Non-Inferior Exposure Compared with Intravenous Administration in Patients with Relapsed/Refractory Follicular Lymphoma: Primary Analysis of a Pivotal Phase II

A Phase 2 Study of Loncastuximab Tesirine Plus Mosunetuzumab in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only